Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Toxicology
Published in: Cardiovascular Toxicology 2/2019

01-04-2019

An Overview on Arsenic Trioxide-Induced Cardiotoxicity

Authors: Vadavanath Prabhakaran Vineetha, Kozhiparambil Gopalan Raghu

Published in: Cardiovascular Toxicology | Issue 2/2019

Login to get access

Abstract

Arsenic trioxide (ATO) is among the first-line chemotherapeutic drugs used in oncological practice. It has shown substantial efficacy in treating patients with relapsed or refractory acute promyelocytic leukaemia. The clinical use of ATO is hampered due to cardiotoxicity and hence many patients are precluded from receiving this highly effective treatment. An alternative to this would be to use any drug that can ameliorate the cardiotoxic effects and allow exploiting the full therapeutic potential of ATO, with considerable impact on cancer therapy. Generation of reactive oxygen species is involved in a wide range of human diseases, including cancer, cardiovascular, pulmonary and neurological disorders. Hence, agents with the ability to protect against these reactive species may be therapeutically useful. The present review focuses on the beneficial as well as harmful effects of arsenic and ATO, the mechanisms underlying ATO toxicity and the possible ways that can be adopted to circumvent ATO-induced toxicity.
Literature
1.
Fox, E., Razzouk, B. I., Widemann, B. C., Xiao, S., O’Brien, M., Goodspeed, W., Reaman, G. H., Blaney, S. M., Murgo, A. J., Balis, F. M., & Adamson, P. C. (2008). Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood, 111, 566–573.CrossRefPubMedPubMedCentral
2.
Mathews, V., Chendamarai, E., George, B., Viswabandya, A., & Srivastava, A. (2011). Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterranean Journal of Hematology and Infectious Diseases, 3, e2011056.CrossRefPubMedPubMedCentral
3.
Drolet, B., Simard, C., & Roden, D. M. (2004). Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation, 109, 26–29.CrossRefPubMed
4.
Mumford, J. L., Wu, K., Xia, Y., Kwok, R., Yang, Z., Foster, J., & Sanders, W. E. (2007). Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study. Environmental Health Perspectives, 115, 690–694.CrossRefPubMedPubMedCentral
5.
Ducas, R. A., Seftel, M. D., Ducas, J., & Seifer, C. (2011). Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia. The Journal of the Royal College of Physicians of Edinburgh, 41, 117–118.CrossRefPubMed
6.
Costa, V. M., Carvalho, F., Duarte, J., Bastos, M. L., & Remião, F. (2013). The heart as a target for xenobiotic toxicity: The cardiac susceptibility to oxidative stress. Chemical Research in Toxicology, 26, 1285–1311.CrossRefPubMed
7.
Vineetha, V. P., Soumya, R. S., & Raghu, K. G. (2015). Phloretin ameliorates arsenic trioxide induced mitochondrial dysfunction in H9c2 cardiomyoblasts mediated via alterations in membrane permeability and ETC complexes. European Journal of Pharmacology, 754, 162–172.CrossRefPubMed
8.
Gupta, S., Das, B., & Sen, S. (2007). Cardiac hypertrophy: Mechanisms and therapeutic opportunities. Antioxidants & Redox Signaling, 9, 623–652.CrossRef
9.
Hughes, M. F., Beck, B. D., Chen, Y., Lewis, A. S., & Thomas, D. J. (2011). Arsenic exposure and toxicology: A historical perspective. Toxicological Sciences, 123, 305–332.CrossRefPubMedPubMedCentral
10.
Cervantes, C., Ji, G., Ramirez, J. L., & Silver, S. (1994). Resistance to arsenic compounds in microorganisms. FEMS Microbiology Reviews, 15, 355–367.CrossRefPubMed
11.
European Food Safety Authority (EFSA) and EFSA Panel on Contaminants in the Food Chain (CONTAM). (2009). Scientific opinion on arsenic in food. EFSA Journal, 7, 199.
12.
Smedley, P. L., & Kinniburgh, D. G. (2002). A review of the source, behaviour and distribution of arsenic in natural waters. Applied Geochemistry, 17, 517–568.CrossRef
13.
Lantz, R. C., & Hays, A. M. (2006). Role of oxidative stress in arsenic-induced toxicity. Drug Metabolism Reviews, 38, 791–804.CrossRefPubMed
14.
Schuhmacher-Wolz, U., Dieter, H. H., Klein, D., & Schneider, K. (2009). Oral exposure to inorganic arsenic: Evaluation of its carcinogenic and non-carcinogenic effects. Critical Reviews in Toxicology, 39, 271–298.CrossRefPubMed
15.
National Research Council (NRC). (1999). Arsenic in drinking water. Washington, DC: National Academy Press.
16.
Chen, C. J., Chuang, Y. C., Lin, T. M., & Wu, H. Y. (1985). Malignant neoplasms among residents of a blackfoot disease endemic area in Taiwan: High arsenic artesian well water and cancers. Cancer Research, 45, 5895–5899.PubMed
17.
Argos, M., Kalra, T., Rathouz, P. J., Chen, Y., Pierce, B., Parvez, F., Islam, T., Ahmed, A., Rakibuz-Zaman, M., Hasan, R., Sarwar, G., Slavkovich, V., van Geen, A., Graziano, J., & Ahsan, H. (2010). Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): A prospective cohort study. The Lancet, 376, 252–258.CrossRef
18.
Nordstrom, D. K. (2002). Public health. Worldwide occurrences of arsenic in ground water. Science, 296, 2143–2145.CrossRefPubMed
19.
International Agency for Cancer Research (IARC). (2004). Some drinking-water disinfectants and contaminants, including arsenic. In IARC monographs on the evaluation of carcinogenic risks to humans, Lyon: International Agency for Cancer Research (IARC), pp 39–267.
20.
Smith, A. H., Lingas, E. O., & Rahman, M. (2000). Contamination of drinking-water by arsenic in Bangladesh: A public health emergency. Bulletin of the World Health Organization, 78, 1093–1103.PubMedPubMedCentral
21.
World Health Organisation (WHO) (1993). Guidelines for drinking-water quality. 2nd edn. Geneva: WHO, ISBN 924, p. 154460.
22.
Environmental protection Agency (EPA). (2001). Natural primary drinking water regulations; Arsenic and clarifications to compliance and new source contaminants monitoring; proposed rule. Federal Register, 66(78), 20580.
23.
Murgo, A. J. (2001). Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the national cancer institute cooperative research and development studies. The Oncologist, 6, 22–28.CrossRefPubMed
24.
Shibata, T., Solo-Gabriele, H. M., Fleming, L. E., Cai, Y., & Townsend, T. G. (2007). A mass balance approach for evaluating leachable arsenic and chromium from an inservice CCA-treated wood structure. Science of the Total Environment, 372, 624–635.CrossRefPubMed
25.
Smith, A. H., Hopenhayn-Rich, C., Bates, M. N., Goeden, H. M., Hertz-Picciotto, I., Duggan, H. M., Wood, R., Kosnett, M. J., & Smith, M. T. (1992). Cancer risks from arsenic in drinking water. Environmental Health Perspectives, 97, 259–267.CrossRefPubMedPubMedCentral
26.
27.
Chou, W. C., Hawkins, A. L., Barrett, J. F., Griffin, C. A., & Dang, C. V. (2001). Arsenic inhibition of telomerase transcription leads to genetic instability. Journal of Clinical Investigation, 108, 1541–1547.CrossRefPubMedPubMedCentral
28.
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995). Telomere elongation in immortal human cells without detectable telomerase activity. EMBO Journal, 14, 4240–4248.CrossRefPubMed
29.
Gallagher, R. E. (1998). Arsenic: New life for an old potion. New England Journal of Medicine, 339, 1389–1391.CrossRefPubMed
30.
Shim, M. J., Kim, H. J., Yang, S. J., Lee, I. S., Choi, H. I., & Kim, T. (2002). Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: Possible involvement of p38 MAP kinase. Journal of Biochemistry and Molecular Biology, 35, 377–383.PubMed
31.
Florea, A. M. (2005). Toxicity of alkylated derivatives of arsenic, antimony and tin: Cellular uptake, cytotoxicity, genotoxic effects, perturbation of Ca 2+ homeostasis and cell death. Aachen: Shaker Verlag.
32.
Griffin, R. J., Williams, B. W., Park, H. J., & Song, C. W. (2005). Preferential action of arsenic trioxide in solid-tumour microenvironment enhances radiation therapy. International Journal of Radiation Oncology Biology Physics, 61, 1516–1522.CrossRef
33.
Florea, A. M., & Büsselberg, D. (2006). Metals and metal compounds: Occurrence, use, benefits and toxic cellular effects. BioMetals, 19, 419–427.CrossRefPubMed
34.
35.
Antman, K. H. (2001). Introduction: The history of arsenic trioxide in cancer therapy. The Oncologist, 6, 1–2.CrossRefPubMed
36.
Chen, C. J., Hsueh, Y. M., Lai, M. S., Shyu, M. P., Chen, S. Y., Wu, M. M., Kuo, T. L., & Tai, T. Y. (1995). Increased prevalence of hypertension and long-term arsenic exposure. Hypertension, 25, 53–60.CrossRefPubMed
37.
Tallman, M. S. (2007). Treatment of relapsed or refractory acute promyelocytic leukemia. Best Practice & Research Clinical Haematology, 20, 57–65.CrossRef
38.
Platanias, L. C. (2009). Biological responses to arsenic compounds. Journal of Biological Chemistry, 284, 18583–18587.CrossRefPubMed
39.
Iland, H. J., & Seymour, J. F. (2013). Role of arsenic trioxide in acute promyelocytic leukemia. Current Treatment Options in Oncology, 14, 170–184.CrossRefPubMed
40.
Mi, J. (2011). Current treatment strategy of acute promyelocytic leukemia. Frontiers in Medicine, 5, 341–347.CrossRef
41.
Baj, G., Arnulfo, A., Deaglio, S., Mallone, R., Vigone, A., De Cesaris, M. G., Surico, N., Malavasi, F., & Ferrero, E. (2002). Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Research and Treatment, 73, 61–73.CrossRefPubMed
42.
de The, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990). The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature, 347, 558–561.CrossRefPubMed
43.
Borrow, J., Goddard, A. D., Sheer, D., & Solomon, E. (1990). Molecular analysis of acute promyelocytic leukemia break point cluster region on chromosome 17. Science, 249, 1577–1580.CrossRefPubMed
44.
Dyck, J. A., Maul, G. G., Miller, W. H. Jr., Chen, J. D., Kakizuka, A., & Evans, R. M. (1994). A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell, 76, 333–343.CrossRefPubMed
45.
Mu, Z. M., Chin, K. V., Liu, J. H., Lozano, G., & Chang, K. S. (1994). PML, a growth suppressor disrupted in acute promyelocytic leukemia. Molecular and Cellular Biology, 14, 6858–6867.CrossRefPubMedPubMedCentral
46.
Chang, K. S., Fan, Y. H., Andreeff, M., Liu, J., & Mu, Z. M. (1995). The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood, 85, 12.
47.
Shao, W., Fanelli, M., Ferrara, F. F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W. W., Waxman, S., Pelicci, P. G., Lo Coco, F., Avvisati, G., Testa, U., Peschle, C., Gambacorti-Passerini, C., Nervi, C., & Miller, W. H. J. (1998). Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. Journal of the National Cancer Institute (1988), 90, 124–133.CrossRef
48.
Zhang, X. W., Yan, X. J., Zhou, Z. R., Yang, F. F., Wu, Z. Y., Sun, H. B., Liang, W. X., Song, A. X., Lallemand-Breitenbach, V., Jeanne, M., Zhang, Q. Y., Yang, H. Y., Huang, Q. H., Zhou, G. B., Tong, J. H., Zhang, Y., Wu, J. H., Hu, H. Y., deThe, H., Chen, S. J., & Chen, Z. (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 328, 240–243.CrossRefPubMed
49.
Mi, J.-Q., Li, J.-M., Shen, Z.-X., Chen, S.-J., & Chen, Z. (2012). How to manage acute promyelocytic leukemia. Leukemia, 26, 1743–1751.CrossRefPubMed
50.
Sun, H. D. M. L., Hu, X. C., & Zhang, T. D. (1992). Thirty two cases of treating acute promyelocytic leukemia by Ailing I therapy combined with syndrome differentiation treatment of traditional Chinese medicine. Chinese Journal Combinat Traditional Chinese Medicine West Medicine, 1996, 170–171.
51.
Zhang, P. (1999). The use of arsenic trioxide in the treatment of acute promyelocytic leukemia. Journal of Biological Regulators and Homeostatic Agents, 13, 195–200.PubMed
52.
Soignet, S. L., Frankel, S. R., Douer, D., Tallmann, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., Sievers, E. L., Coutre, S., Dahlberg, S., Ellison, R., & Warrell, R. P. Jr. (2001). United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology, 19, 3852–3860.CrossRefPubMed
53.
Fenaux, P., Chomienne, C., & Degos, L. (2001). Treatment of acute promyelocytic leukaemia. Best Practice & Research: Clinical Haematology, 14, 153–174.
54.
Zhu, J., Chen, Z., Lallemand-Breitenbach, V., & de The, H. (2002). How acute promyelocytic leukaemia revived arsenic. Nature Reviews Cancer, 2, 705–713.CrossRefPubMed
55.
Chen, C. J., Chiou, H. Y., Chiang, M. H., Lin, L. J., & Tai, T. Y. (1996). Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arteriosclerosis, Thrombosis, and Vascular Biology, 16, 504–510.CrossRefPubMed
56.
Abaza, Y., Kantarjian, H., Garcia-Manero, G., Estey, E., Borthakur, G., Jabbour, E., Faderl, S., O’Brien, S., Wierda, W., Pierce, S., Brandt, M., McCue, D., Luthra, R., Patel, K., Kornblau, S., Kadia, T., Daver, N., DiNardo, C., Jain, N., Verstovsek, S., Ferrajoli, A., Andreeff, M., Konopleva, M., Estrov, Z., Foudray, M., McCue, D., Cortes, J., & Ravandi, F. (2017). Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 129, 1275–1283.CrossRefPubMedPubMedCentral
57.
Hosseini, R., Mandegary, A., Alimoghaddam, K., Ghavamzadeh, A., & Ghahremani, M. H. (2008). Pharmacokinetic of arsenic trioxide in newly diagnosed acute promyelocytic leukemia patients. Journal of Applied Sciences, 8, 4617–4623.CrossRef
58.
Shen, Y., Shen, Z. X., Yan, H., Chen, J., Zeng, X. Y., Li, J. M., Li, X. S., Wu, W., Xiong, S. M., Zhao, W. L., Tang, W., Wu, F., Liu, Y. F., Niu, C., Wang, Z. Y., Chen, S. J., & Chen, Z. (2001). Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage. Leukemia, 15, 735–741.CrossRefPubMed
59.
Wang, Z., Zhou, J., Lu, X., Gong, Z., & Le, X. C. (2004). Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chemical Research in Toxicology, 17, 95–103.CrossRefPubMed
60.
Fukai, Y., Hirata, M., Ueno, M., Ichikawa, N., Kobayashi, H., Saitoh, H., Sakurai, T., Kinoshita, K., Kaise, T., & Ohta, S. (2006). Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: Speciation of arsenic metabolites in serum and urine. Biological & and Pharmaceutical Bulletin, 29, 1022–1027.CrossRef
61.
Fowler, B. A., Chou, S. J., Jones, R. L., & Chen, C. J. (2007). Arsenic. In G. F. Nordberg, B. A. Fowler, M. Nordberg, L. T. Freiberg (Eds.), Handbook on the toxicology of metals (pp. 367–443). Amsterdam: Elsevier.CrossRef
62.
Shen, Z. X., Chen, G. Q., Ni, J. H., Li, X. S., Xiong, S. M., Qiu, Q. Y., Zhu, J., Tang, W., Sun, G. L., Yang, K. Q., Chen, Y., Zhou, L., Fang, Z. W., Wang, Y. T., Ma, J., Zhang, P., Zhang, T. D., Chen, S. J., Chen, Z., & Wang, Z. Y. (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89, 3354–3360.PubMed
63.
Ni, J., Chen, G., Shen, Z., Li, X., Liu, H., Huang, Y., Fang, Z., Chen, S., Wang, Z., & Chen, Z. (1998). Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chinese Medical Journal, 111, 1107–1110.PubMed
64.
Hua, H., Qin, S., Rui, J., & Li, J. (2011). Pharmacokinetics of arsenic trioxide (As2O3) in Chinese primary hepatocarcinoma patients. Asian Pacific Journal of Cancer Prevention, 12, 61–65.PubMed
65.
Schoen, A., Beck, B., Sharma, R., & Dube, E. (2004). Arsenic toxicity at low doses: Epidemiological and mode of action considerations. Toxicology and Applied Pharmacology, 198, 253–267.CrossRefPubMed
66.
Singh, A. P., Goel, R. K., & Kaur, T. (2011). Mechanisms pertaining to arsenic toxicity. International Journal of Toxicology, 18, 87–93.CrossRef
67.
Miller, W. H., Schipper, H. M., Lee, J. S., Singer, J., & Waxman, S. (2002). Mechanisms of action of arsenic trioxide. Cancer Research, 62, 3893–3903.PubMed
68.
Lau, A. T., Li, M., Xie, R., He, Q. Y., & Chiu, J. F. (2004). Opposed arsenite-induced signalling pathways promote cell proliferation or apoptosis in cultured lung cells. Carcinogenesis, 25, 21–28.CrossRefPubMed
69.
Benbrahim-Tallaa, L., Webber, M. M., & Waalkes, M. P. (2007). Mechanisms of acquired androgen independence during arsenic-induced malignant trans-formation of human prostate epithelial cells. Environmental Health Perspectives, 115, 243–247.CrossRefPubMed
70.
Chen, H., Liu, J., Zhao, C. Q., Diwan, B. A., Merrick, B. A., & Waalkes, M. P. (2001). Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicology and Applied Pharmacology, 175, 260–268.CrossRefPubMed
71.
Benbrahim-Tallaa, L., Webber, M. M., & Waalkes, M. P. (2005). Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation. Environmental Health Perspectives, 113, 1134–1139.CrossRefPubMedPubMedCentral
72.
Kitchin, K. T. (2001). Recent advances in arsenic carcinogenesis: Modes of action, animal model systems, and methylated arsenic metabolites. Toxicology and Applied Pharmacology, 172, 249–261.CrossRefPubMed
73.
Zhao, C. Q., Young, M. R., Diwan, B. A., Coogan, T. P., & Waalkes, M. P. (1997). Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proceedings of the National Academy of Sciences of the United States of America, 94, 10907–10912.CrossRefPubMedPubMedCentral
74.
Jensen, T. J., Novak, P., Eblin, K. E., Gandolfi, A. J., & Futscher, B. W. (2008). Epigenetic remodeling during arsenical-induced malignant transformation. Carcinogenesis, 29, 1500–1508.CrossRefPubMedPubMedCentral
75.
Chow, S. K., Chan, J. Y., & Fung, K. P. (2004). Suppression of cell proliferation and regulation of estrogen receptor alpha signalling pathway by arsenic trioxide on human breast cancer MCF-7 cells. Journal of Endocrinology, 182, 325–337.CrossRefPubMed
76.
Chen, G. C., Guan, L. S., Hu, W. L., & Wang, Z. Y. (2002). Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells. Anticancer Research, 22, 633–638.PubMed
77.
Roboz, G. J., Dias, S., Lam, G., Lane, W. J., Soignet, S. L., Warrell, R. P., & Rafii, S. (2000). Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood, 96, 1523–1530.
78.
Qian, Y., Castranova, V., & Shi, X. (2003). New perspectives in arsenic-induced cell signal transduction. Journal of Inorganic Biochemistry, 96, 271–278.CrossRefPubMed
79.
Barbey, J. T., & Soignet, S. (2001). Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Annals of Internal Medicine, 135, 842–843.CrossRefPubMed
80.
Westervelt, P., Brown, R. A., Adkins, D. R., Khoury, H., Curtin, P., Hurd, D., Luger, S. M., Ma, M. K., Ley, T. J., & DiPersio, J. F. (2001). Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood, 98, 266–271.CrossRefPubMed
81.
82.
Driver, J. A., Djousse´, L., Logroscino, G., Gaziano, J. M., & Kurth, T. (2008). Incidence of cardiovascular disease and cancer in advanced age: Prospective cohort study. The BMJ 337, a2467.CrossRefPubMedPubMedCentral
83.
Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010). Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. Journal of the National Cancer Institute (1988), 102, 14–25.CrossRef
84.
Bovelli, D., Plataniotis, G., Roila, F.,& On behalf of the ESMO Guidelines Working Group (2010). Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Annals of Oncology 21, v277–v282.CrossRefPubMed
85.
Morganroth, J., Brozovich, F. V., McDonald, J. T., & Jacobs, R. A. (1991). Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. American Journal of Cardiology, 67, 774–776.CrossRefPubMed
86.
Unnikrishnann, D., Dutcher, J. P., Varshneya, N., Lucariello, R., Api, M., Garl, S., Wiernik, P. H., & Chiaramida, S. (2001). Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood, 97, 1514–1516.CrossRef
87.
Ficker, E., Kuryshev, Y. A., Dennis, A. T., Obejero-Paz, C., Wang, L., Hawryluk, P., Wible, B. A., & Brown, A. M. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. Molecular Pharmacology, 66, 33–44.CrossRefPubMed
88.
Clancy, C. E., Kurokawa, J., Tateyama, M., Wehrens, X. H. T., & Kass, R. S. (2003). K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annual Review of Pharmacology and Toxicology, 43, 441–461.CrossRefPubMed
89.
Taglialatela, M., Castaldo, P., Iossa, S., Pannaccione, A., Fresi, A., Ficker, E., & Annunziato, L. (1997). Regulation of the human ether-a-go go related gene (HERG) K+ channels by reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America, 94, 11698–11703.CrossRefPubMedPubMedCentral
90.
Berube, J., Caouette, D., & Daleau, P. (2001). Hydrogen peroxide modifies the kinetics of HERG channel expressed in a mammalian cell line. Journal of Pharmacology and Experimental Therapeutics, 297, 96–102.PubMed
91.
92.
van Noord, C., Eijgelsheim, M., & Stricker, B. H. (2010). Drug- and non-drug-associated QT interval prolongation. British Journal of Clinical Pharmacology, 70, 16–23.CrossRefPubMedPubMedCentral
93.
Ott, M., Gogvadze, V., Orrenius, S., & Zhivotovsky, B. (2007). Mitochondria, oxidative stress and cell death. Apoptosis, 12, 913–922.CrossRef
94.
Rana, S. V. (2008). Metals and apoptosis: Recent developments. Journal of Trace Elements in Medicine and Biology, 22, 262–284.CrossRefPubMed
95.
96.
Willcox, J. K., Ash, S. L., & Catignani, G. L. (2004). Antioxidants and prevention of chronic disease. Critical Reviews in Food Science and Nutrition, 44, 275–295.CrossRefPubMed
97.
Fang, Y. Z. (2002). Free radicals and nutrition. In Y. Z. Fang, Zheng & RL (Eds.), Theory and application of free radical biology (p. 647). Beijing: Scientific Press.
98.
Shi, H., Hudson, L. G., Ding, W., Wang, S., Cooper, K. L., Liu, S., Chen, Y., Shi, X., & Liu, K. J. (2004). Arsenite causes DNA damage in keratinocytes via generation of hydroxyl radicals. Chemical Research in Toxicology, 17, 871–878.CrossRefPubMed
99.
Woo, S. H., Park, I. C., Park, M. J., Lee, H. C., Lee, S. J., Chun, Y. J., Lee, S. H., Hong, S. I., & Rhee, C. H. (2002). Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. International Journal of Oncology, 21, 57–63.PubMed
100.
Han, Y. H., Moon, H. J., You, B. R., Kim, S. Z., Kim, S. H., & Park, W. H. (2010). Effects of arsenic trioxide on cell death, reactive oxygen species and glutathione levels in different cell types. International Journal of Molecular Medicine, 25, 121–128.PubMed
101.
Sun, Y., Wang, C., Wang, L., Dai, Z., & Yang, K. (2018). Arsenic trioxide induces apoptosis and the formation of reactive oxygen species in rat glioma cells. Cellular & Molecular Biology Letters, 23, 13.CrossRef
102.
Hagen, T. M., Wehr, C. M., & Ames, B. N. (1998). Mitochondrial decay in aging. Reversal through supplementation of acetyl-Lcarnitine and N-tert-butyl-alpha-phenyl-nitrone. Annals of the New York Academy of Sciences, 854, 214–223.CrossRefPubMed
103.
Bahorun, T., Soobratte, M. A., Luximon-Ramma, V., & Aruoma, O. I. (2006). Free radicals and antioxidants in cardiovascular health and disease. Internet Journal of Medical Update, 1, 25–41.
104.
Cadenas, E., & Davies, K. J. A. (2000). Mitocondrial free radical generation, oxidative stress, and aging. Free Radical Biology and Medicine, 29, 222–230.CrossRefPubMed
105.
Mieyal, J. J., Gallogly, M. M., Qanungo, S., Sabens, E. A., & Shelton, M. D. (2008). Molecular mechanisms and clinical implications of reversible protein s-glutathionylation. Antioxidants & Redox Signaling, 10, 1941–1988.CrossRef
106.
Anderson, T. J., Meredith, I. T., Yeung, A. C., Frei, B., Selwyn, A. P., & Ganz, P. (1995). The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New England Journal of Medicine, 332, 488–493.CrossRefPubMed
107.
Guzik, T. J., West, N. E. J., Black, E., McDonald, D., Ratnatunga, C., Pillai, R., & Channon, K. M. (2000). Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circulation Research, 86, e85–e90.PubMed
108.
Heymes, C., Bendall, J. K., Ratajczak, P., Cave, A. C., Samuel, J. L., Hasenfuss, G., & Shah, A. M. (2003). Increased myocardial NADPH oxidase activity in human heart failure. Journal of the American College of Cardiology, 41, 2164–2171.CrossRefPubMed
109.
Halliwell, B. (2011). Free radicals and antioxidants-quo vadis? Trends in Pharmacological Sciences, 32, 125–130.CrossRefPubMed
110.
Chance, B., Sies, H., & Boveris, A. (1979). Hydroperoxide metabolism in mammalian organs. Physiological Reviews, 59, 527–605.CrossRefPubMed
111.
Hwang, J. T., Kwon, D. Y., Park, O. J., & Kim, M. S. (2008). Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes & Nutrition, 2, 323–326.CrossRef
112.
Gomes, E. C., Silva, A. N., & de Oliveira, M. R. (2012). Oxidants, antioxidants, and the beneficial roles of exercise-induced production of reactive species. Oxidative Medicine and Cellular Longevity, 2012, 12.CrossRef
113.
Ursini, F., Maiorino, M., & Brigelius-Flohé, R. (1995). The diversity of glutathione peroxidase. Methods in Enzymology, 252, 38–63.CrossRefPubMed
114.
Vineetha, V. P., Girija, S., Soumya, R. S., & Raghu, K. G. (2014). Polyphenol-rich apple (Malus domestica L.) peel extract attenuates arsenic trioxide induced cardiotoxicity in H9c2 cells via its antioxidant activity. Food & Function, 5, 502–511.CrossRef
115.
Brookes, P. S., Yoon, Y., Robotham, J. L., Anders, M. W., & Sheu, S. S. (2004). Calcium, ATP, and ROS: A mitochondrial love-hate triangle. American Journal of Physiology. Cell Physiology, 287, 817–833.CrossRef
116.
117.
Berridge, M. J., Lipp, P., & Bootman, M. D. (2000). The versatility and universality of calcium signalling. Nature Reviews Molecular Cell Biology, 1, 11–21.CrossRefPubMed
118.
Orrenius, S., Zhivotovsky, B., & Nicotera, P. (2003). Regulation of cell death: The calcium-apoptosis link. Nature Reviews Molecular Cell Biology, 4, 552–565.CrossRefPubMed
119.
Berridge, M. J., Bootman, M. D., & Roderick, H. L. (2003). Calcium signalling: Dynamics, homeostasis and remodelling. Nature Reviews Molecular Cell Biology, 4, 517–529.CrossRefPubMed
120.
Rizzuto, R., Brini, M., Murgia, M., & Pozzan, T. (1993). Microdomains with high Ca2+ close to IP3-sensitive channels that are sensed by neighbouring mitochondria. Science, 262, 744–747.CrossRefPubMed
121.
Wang, Y., & Goldhaber, J. I. (2004). Return of calcium: Manipulating intracellular calcium to prevent cardiac pathologies. Proceedings of the National Academy of Sciences of the United States of America, 101, 5697–5698.CrossRefPubMedPubMedCentral
122.
Sitsapesan, R., & Williams, A. J. (2000). Do inactivation mechanisms rather than adaptation hold the key to understanding ryanodine receptor channel gating? Journal of General Physiology, 116, 867–872.CrossRefPubMed
123.
Eisner, D. A., Trafford, A. W., Diaz, M. E., Overend, C. L., & O’Neill, S. C. (1998). The control of Ca release from the cardiac sarcoplasmic reticulum: Regulation versus autoregulation. Cardiovascular Research, 38, 589–604.CrossRefPubMed
124.
Florea, A. M., Yamoah, E. N., & Dopp, E. (2005). Intracellular calcium disturbances induced by arsenic and its methylated derivatives in relation to genomic damage and apoptosis induction. Environmental Health Perspectives, 113, 659–664.CrossRefPubMedPubMedCentral
125.
Zhang, J., Sun, G., Wang, M., Liao, P., Du, Y., Yang, K., & Sun, X. (2016). Arsenic trioxide triggered calcium homeostasis imbalance and induced endoplasmic reticulum stress-mediated apoptosis in adult rat ventricular myocytes. Toxicology Research, 5, 682–688.CrossRefPubMedPubMedCentral
126.
Ohnishi, K., Yoshida, H., Shigeno, K., Nakamura, S., Fujisawa, S., Naito, K., Shinjo, K., Fujita, Y., Matsui, H., & Takeshita, A. (2000). Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Annals of Internal Medicine, 133, 881–885.CrossRefPubMed
127.
Yedjou, C. G., & Tchouwou, P. B. (2007). In-vitro cytotoxic and genotoxic effects of arsenic trioxide on human leukemia (HL-60) cells using the MTT and alkaline single cell electrophoresis (comet) assays. Molecular and Cellular Biochemistry, 301, 123–130.CrossRefPubMedPubMedCentral
128.
Michel, L., Dupuy, A., Jean-Louis, F., Sors, A., Poupon, J., Viguier, M., Musette, P., Dubertret, L., Degos, L., Dombret, H., & Bachelez, H. (2003). Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: Evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). The Journal of Investigative Dermatology, 121, 881–893.CrossRefPubMed
129.
Huang, H. S., Chang, W. C., & Chen, C. J. (2002). Involvement of reactive oxygen species in arsenite-induced down regulation of phospholipid hydroperoxide glutathione peroxidase in human epidermoid carcinoma A431 cells. Free Radical Biology and Medicine, 33, 864–873.CrossRefPubMed
130.
Graham-Evans, B., Cohly, H. H. P., Yu, H., & Tchounwou, P. B. (2004). Arsenic-induced genotoxic and cytotoxic effects in human keratinocytes, melanocytes and dendritic cells. International Journal of Environmental Research and Public Health, 1, 83–89.CrossRefPubMed
131.
Waclavicek, M., Berer, A., Oehler, L., Stöckl, J., Schloegl, E., Majdic, O., & Knapp, W. (2001). Calcium ionophore: A single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells. British Journal of Haematology, 114, 466–473.CrossRefPubMed
132.
Parag, H. A., Raboy, B., & Kulka, R. G. (1987). Effects of heat shock on protein degradation in mammalian cells involvement of the ubiquitin system. EMBO Journal, 6, 55–61.CrossRefPubMed
133.
Matsui, M., Nishigori, C., Toyokuni, S., Takada, J., Akaboshi, M., Ishikawa, M., Imamura, S., & Miyachi, Y. (1999). The role of oxidative DNA damage in human arsenic carcinogenesis: Detection of 8-hydroxy-2′- deoxyguanosine in arsenic-related Bowen’s disease. The Journal of Investigative Dermatology, 113, 26–31.CrossRefPubMed
134.
Alarifi, S., Ali, D., Alkahtani, S., Siddiqui, M. A., & Ali, B. A. (2013). Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells. OncoTargets and Therapy, 6, 75–84.PubMedPubMedCentral
135.
Nordenson, I., & Beckman, L. (1991). Is the genotoxic effect of arsenic mediated by oxygen free radicals? Human Heredity, 41, 71–73.CrossRefPubMed
136.
Barchowsky, A., Klei, L. R., Dudek, E. J., Swartz, H. M., & James, P. E. (1999). Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radical Biology and Medicine, 27, 1405–1412.CrossRefPubMed
137.
Smith, K. R., Klei, L. R., & Barchowsky, A. (2001). Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. American Journal of Physiology-Lung Cellular and Molecular Physiology, 280, L442–L449.CrossRefPubMed
138.
Bunderson, M., Brooks, D. M., Walker, D. L., Rosenfeld, M. E., Coffin, J. D., & Beall, H. D. (2004). Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicology and Applied Pharmacology, 201, 32–39.CrossRefPubMed
139.
Lee, P. C., Ho, I. C., & Lee, T. C. (2005). Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicological Sciences, 85, 541–550.CrossRefPubMed
140.
Pysher, M. D., Chen, Q. M., & Vaillancourt, R. R. (2008). Arsenic alters vascular smooth muscle cell focal adhesion complexes leading to activation of FAK-src mediated pathways. Toxicology and Applied Pharmacology, 231, 135–141.CrossRefPubMedPubMedCentral
141.
Tsai, S. H., Hsieh, M. S., Chen, L., Liang, Y. C., Lin, J. K., & Lin, S. Y. (2001). Suppression of Fas ligand expression on endothelial cells by arsenite through reactive oxygen species. Toxicology Letters, 123, 11–19.CrossRefPubMed
142.
Chen, S. C., Tsai, M. H., Wang, H. J., Yu, H. S., & Chang, L. W. (2007). Involvement of substance P and neurogenic inflammation in arsenic-induced early vascular dysfunction. Toxicological Sciences, 95, 82–88.CrossRefPubMed
143.
Pereira, F. E., Coffin, J. D., & Beall, H. D. (2007). Activation of protein kinase C and disruption of endothelial monolayer integrity by sodium arsenite-potential mechanism in the development of atherosclerosis. Toxicology and Applied Pharmacology, 220, 164–177.CrossRefPubMedPubMedCentral
144.
Tsou, T. C., Tsai, F. Y., Hsieh, Y. W., Li, L. A., Yeh, S. C., & Chang, L. W. (2005). Arsenite induces endothelial cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase. Toxicology and Applied Pharmacology, 208, 277–284.CrossRefPubMed
145.
Balakumar, P., & Kaur, J. (2009). Arsenic exposure and cardiovascular disorders: An overview. Cardiovascular Toxicology, 9, 169–176.CrossRefPubMed
146.
Lee, M. Y., Lee, Y. H., Lim, K. M., Chung, S. M., Bae, O. N., Kim, H., Lee, C. R., Park, J. D., & Chung, J. H. (2005). Inorganic arsenite potentiates vasoconstriction through calcium sensitization in vascular smooth muscle. Environmental Health Perspectives, 113, 1330–1335.CrossRefPubMedPubMedCentral
147.
Raghu, K. G., & Cherian, O. L. (2009). Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes. Journal of Trace Elements in Medicine and Biology, 23, 61–68.CrossRefPubMed
148.
Zhao, J. L., Sun, B. G., Wen, Q. Z., Zhang, J. J., Jin, W., Xue, J. X., & Zhuang, W. Y. (2007). Effect of early and non-early controlled-release of arsenic-trioxide eluting stents on restenosis inhibition in a canine model. Zhonghua Xin Xue Guan Bing Za Zhi, 35, 571–574.PubMed
149.
Gill, C., Mestril, R., & Sali, A. (2002). Losing heart; The role of apoptosis in heart disease-noval therapeutic target. The FASEB Journal, 16, 135–146.CrossRefPubMed
150.
Nerheim, P., Krishnan, S. C., Olshansky, B., & Shivkumar, K. (2001). Apoptosis in the genesis of cardiac rhythm disorders. Cardiology Clinics, 19, 155–163.CrossRefPubMed
151.
James, T. N. (1996). Long reflections on the QT interval: The sixth annual Gordon K. Moe Lecture. Journal of Cardiovascular Electrophysiology, 7, 738–759.CrossRefPubMed
152.
Best, P. J., Hasdai, D., Sangiorgi, G., Schwartz, R. S., Holmes, D. R. Jr., & Simari, R. D. (1999). Apoptosis. Basic concepts and implications in coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 14–22.CrossRefPubMed
153.
Jacobson, M. D. (1996). Reactive oxygen species and programmed cell death. Trends in Biochemical Sciences, 21, 83–86.CrossRefPubMed
154.
Zhao, X., Feng, T., Chen, H., Shan, H., Zhang, Y., Lu, Y., & Yang, B. (2008). Arsenic trioxide-induced apoptosis in H9c2 cardiomyocytes: Implications in cardiotoxicity. Basic & Clinical Pharmacology & Toxicology, 102, 419–425.CrossRef
155.
Hei, T. K., Liu, S. X., & Waldren, C. (1998). Mutagenicity of arsenic in mammalian cells: Role of reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America, 5, 8103–8107.CrossRef
156.
Szeto, H. H. (2006). Cell permeable, mitochondrial-target, peptide antioxidants. American Association of Pharmaceutical Scientists Journal, 8, 277–278.
157.
Dillard, C. J., & German, J. B. (2000). Phytochemicals: Nutraceuticals and human health. Journal of the Science of Food and Agriculture, 80, 1744–1756.CrossRef
158.
Gu, J., Gui, Y., Chen, L., Yuan, G., Lu, H., & Xu, X. (2013). Use of natural products as chemical library for drug discovery and network pharmacology. PLoS ONE, 8, e62839.CrossRefPubMedPubMedCentral
159.
Nampoothiri, S. V., Binilraj, S. S., Prathapan, A., Abhilash, P. A., Arumughan, C., & Sundaresan, A. (2011). In vitro antioxidant activities of the methanol extract and its different solvent fractions obtained from the fruit pericarp of Terminalia bellerica. Natural Product Research, 25, 277–287.CrossRefPubMed
160.
Prathapan, A., Vineetha, V. P., Abhilash, P. A., & Raghu, K. G. (2013). Boerhaavia diffusa L. attenuates angiotensin II-induced hypertrophy in H9c2 cardiac myoblast cells via modulating oxidative stress and down-regulating NF-κB and transforming growth factor β1. British Journal of Nutrition, 110, 1201–1210.CrossRefPubMed
161.
Prathapan, A., Vineetha, V. P., & Raghu, K. G. (2014). Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS ONE, 9(4), e96220.CrossRefPubMedPubMedCentral
162.
Vineetha, V. P., Prathapan, A., Soumya, R. S., & Raghu, K. G. (2013). Arsenic trioxide toxicity in H9c2 myoblasts—damage to cell organelles and possible amelioration with Boerhaavia diffusa. Cardiovascular Toxicology, 13, 123–137.CrossRefPubMed
163.
Bouayed, J., & Bohn, T. (2010). Exogenous antioxidants-double-edged swords in cellular redox state: Health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxidative Medicine and Cellular Longevity, 3, 228–237.CrossRefPubMedPubMedCentral
164.
Diplock, A. T., Charleux, J. L., Crozier-Willi, G., Kok, F. J., Rice-Evans, C., Roberfroid, M., Stahl, W., & Viña-Ribes, J. (1998). Functional food science and defence against reactive oxygen species. British Journal of Nutrition, 80, S77–S112.CrossRefPubMed
165.
Howard, B. V., & Kritchevsky, D. (1997). Phytochemicals and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation, 95, 2591–2593.CrossRefPubMed
166.
Hu, F. B. (2003). Plant-based foods and prevention of cardiovascular diseases: An overview. American Journal of Clinical Nutrition, 78, 544S–551S.CrossRefPubMed
167.
Reddy, V. B. M., Sasikala, P., Karthik, A., Sudheer, S. D., & Murthy, L. N. (2012). Protective role of curcumin against arsenic trioxide toxicity during gestation and lactational periods. Global Veterinaria, 9, 270–276.
168.
Zhao, X.-Y., Li, G.-Y., Liu, Y., Chai, L.-M., Chen, J.-X., Zhang, Y., Du, Z.-M., Lu, Y.-J., & Yang, B.-F. (2008). Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo. British Journal of Pharmacology, 154, 105–113.CrossRefPubMedPubMedCentral
169.
Kumazaki, M., Ando, H., Kakei, M., Ushijima, K., Taniguchi, Y., Yoshida, M., Yamato, S., Washino, S., Koshimizu, T. A., & Fujimura, A. (2013). α-Lipoic acid protects against arsenic trioxide-induced acute QT prolongation in anesthetized guinea pigs. European Journal of Pharmacology, 705, 1–10.CrossRefPubMed
170.
Zhang, J.-Y., Wang, M., Wang, R.-Y., Sun, X., Du, Y.-Y., Ye, J.-X., Sun, G.-B., & Sun, X.-B. (2018). Salvianolic acid A ameliorates arsenic trioxide-induced cardiotoxicity through decreasing cardiac mitochondrial injury and promotes its anticancer activity. Frontiers in Pharmacology, 9, 487.CrossRefPubMedPubMedCentral
171.
Sinha, M., Manna, P., & Sil, P. C. (2008). Arjunolic acid attenuates arsenic-induced nephrotoxicity. Pathophysiology, 15, 147–156.CrossRefPubMed
172.
Bors, W., Heller, W., Michel, C., & Saran, M. (1990). Flavonoids as antioxidants: Determination of radical-scavenging efficiencies. Methods in Enzymology, 186, 343–355.CrossRefPubMed
Metadata
Title
An Overview on Arsenic Trioxide-Induced Cardiotoxicity
Authors
Vadavanath Prabhakaran Vineetha
Kozhiparambil Gopalan Raghu
Publication date
01-04-2019
Publisher
Springer US
Published in
Cardiovascular Toxicology / Issue 2/2019
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-018-09504-7

Other articles of this Issue 2/2019

Cardiovascular Toxicology 2/2019 Go to the issue

OriginalPaper

Pregnancy-Associated Plasma Protein A (PAPP-A) Concentration in Population of Healthy Young People: Interactions with Tobacco Smoke and Anti-oxidative Status

OriginalPaper

Ivabradine Aggravates the Proarrhythmic Risk in Experimental Models of Long QT Syndrome

ReviewPaper

Cardiotoxicity of Pesticides: Are Africans at Risk?

OriginalPaper

Effects of Ambient Atmospheric PM2.5, 1-Nitropyrene and 9-Nitroanthracene on DNA Damage and Oxidative Stress in Hearts of Rats

OriginalPaper

Protective Effects of a Novel Agonist of Galanin Receptors Against Doxorubicin-Induced Cardiotoxicity in Rats

OriginalPaper

Airway Exposure to Modified Multi-walled Carbon Nanotubes Perturbs Cardiovascular Adenosinergic Signaling in Mice

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits